Zacks Research Has Negative Estimate for Revvity Q4 Earnings

Revvity Inc. (NYSE:RVTY) – Equities research analysts at Zacks Research dropped their Q4 2026 EPS estimates for Revvity in a research report issued on Tuesday, August 25th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.64 for the quarter, down from their previous forecast of $1.67. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Revvity’s current full-year earnings is $5.36 per share. Zacks Research also issued estimates for Revvity’s Q1 2027 earnings at $1.17 EPS, Q4 2027 earnings at $1.77 EPS and FY2027 earnings at $5.86 EPS.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. During the same quarter in the previous year, the firm earned $1.18 earnings per share. The firm’s revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS.

Several other equities analysts have also recently issued reports on RVTY. Stifel Nicolaus reduced their price objective on Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday, May 6th. TD Cowen reissued a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Barclays raised their price target on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Sanford C. Bernstein assumed coverage on Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 price target for the company. Finally, Evercore reiterated an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $108.36.

Revvity Price Performance

Shares of NYSE:RVTY opened at $126.31 on Thursday. The firm has a market capitalization of $14.09 billion, a price-to-earnings ratio of 60.15, a price-to-earnings-growth ratio of 2.27 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The business’s 50 day simple moving average is $112.94 and its 200-day simple moving average is $100.82. Revvity has a 12 month low of $81.22 and a 12 month high of $126.90.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio is currently 13.33%.

Institutional Investors Weigh In On Revvity

Hedge funds have recently modified their holdings of the stock. Ascentis Independent Advisors acquired a new position in shares of Revvity in the 1st quarter valued at $29,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Revvity in the second quarter valued at about $32,000. MUFG Securities EMEA plc purchased a new stake in shares of Revvity during the 2nd quarter valued at about $34,000. SJS Investment Consulting Inc. raised its holdings in shares of Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after buying an additional 521 shares during the period. Finally, Headlands Technologies LLC acquired a new position in Revvity during the 2nd quarter worth approximately $49,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Zacks raised its FY2026 EPS forecast to $5.38 from $5.25 and its FY2027 forecast to $5.86 from $5.77. Estimates for Q2 2027 and Q1/Q4 2027 were also increased, suggesting analysts see improving earnings momentum beyond the next quarter.
• Positive Sentiment: The revised FY2026 estimate is slightly above the broader consensus of $5.36. Revvity’s latest quarterly results also exceeded expectations, with EPS of $1.41 versus the $1.21 consensus and revenue of $729.7 million versus $703.0 million expected.
• Neutral Sentiment: Zacks maintained a Hold rating, indicating that the higher earnings forecasts have not yet translated into a stronger recommendation. The stock is trading near its 52-week high and carries a relatively elevated price-to-earnings ratio of about 60, which may limit further upside unless earnings growth accelerates. Revvity Faces A New Test After Its Strong Run
• Negative Sentiment: Several near-term and longer-range estimates were trimmed: Q3 2026 EPS fell to $1.27 from $1.30, Q4 2026 to $1.64 from $1.67, Q3 2027 to $1.42 from $1.44, and Q2 2028 to $1.62 from $1.64. These cuts signal some pressure on interim results.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.